Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sodium valproate 199.8mg; valproic acid 87mg (as navalproate 100.3mg) - modified release tablet - 300 mg - active: sodium valproate 199.8mg valproic acid 87mg (as navalproate 100.3mg) excipient: erythrosine ethylcellulose hydrated silica hypromellose   indigo carmine iron oxide black propylene glycol purified water titanium dioxide - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - clopidogrel bisulfate, form ii 97.875mg equivalent to 75 mg free base - film coated tablet - 75 mg - active: clopidogrel bisulfate, form ii 97.875mg equivalent to 75 mg free base excipient: carnauba wax hydrogenated castor oil hyprolose macrogol 6000 mannitol microcrystalline cellulose opadry pink 32k14834 - prevention of vascular ischaemia associated with secondary atherothrombotic events (mi, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome plavix is indicated in combination with aspirin for patients with: · unstable angina or non-st elevation mi. plavix is indicated for early and long-term reduction of atherothrombotic events (myocardial infarction, stroke, vascular death and refractory ischaemia) whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). · st-segment elevation acute myocardial infarction. in this population, plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - disopyramide 150mg (as base) - capsule - 150 mg - active: disopyramide 150mg (as base) excipient: gelatin magnesium stearate maize starch purified talc starch titanium dioxide

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - citric acid 0.384 g; glucose 1.62 g; potassium chloride 0.186 g; sodium bicarbonate 0.336 g; sodium chloride 0.117 g - effervescent tablet - active: citric acid 0.384 g glucose 1.62 g potassium chloride 0.186 g sodium bicarbonate 0.336 g sodium chloride 0.117 g excipient: blackcurrant flavour 502009 ap0551 isopropyl alcohol purified water saccharin sodium

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - glucose monohydrate 3.56 g;  ;  ; potassium chloride 0.3 g;  ; sodium acid citrate 0.53 g; sodium chloride 0.47 g;   - powder for oral solution - active: glucose monohydrate 3.56 g     potassium chloride 0.3 g   sodium acid citrate 0.53 g sodium chloride 0.47 g   excipient: hydrated silica orange flavour saccharin sodium

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - citric acid 0.384 g; glucose 1.62 g; potassium chloride 0.186 g; sodium bicarbonate 0.336 g; sodium chloride 0.117 g - effervescent tablet - active: citric acid 0.384 g glucose 1.62 g potassium chloride 0.186 g sodium bicarbonate 0.336 g sodium chloride 0.117 g excipient: lemon flavour powder 1013096 saccharin sodium

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - citric acid 0.384 g; glucose 1.62 g; potassium chloride 0.186 g; sodium bicarbonate 0.336 g; sodium chloride 0.117 g - effervescent tablet - active: citric acid 0.384 g glucose 1.62 g potassium chloride 0.186 g sodium bicarbonate 0.336 g sodium chloride 0.117 g excipient: raspberry flavour permaseal phs131990 saccharin sodium

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - hyaluronic acid - solution for injection - 8mg/ml - synvisc is indicated for use as a temporary replacement and supplement for synovial fluid to treat pain associated with osteoarthritis in the knee joint and to increase the mobility of this joint by reducing or eliminating pain. there is no data on the long term use of synvisc.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - ketoprofen 100mg - modified release capsule - 100 mg - active: ketoprofen 100mg excipient: colloidal silicon dioxide erythrosine ethylcellulose gelatin non pariel beads, maize starch + sucrose opacode white s-1-7020 patent blue v purified talc shellac sodium laurilsulfate titanium dioxide

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - alimemazine tartrate 0.5 mg/ml; ephedrine hydrochloride 1.5 mg/ml; pholcodine 0.8 mg/ml - linctus - 7.5,4,2.5mg/5ml - active: alimemazine tartrate 0.5 mg/ml ephedrine hydrochloride 1.5 mg/ml pholcodine 0.8 mg/ml